

Human Anti-Human OX40 (ivuxolimab biosimilar) Monoclonal antibody, clone ivuxolimab (CABT-CS392)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Specificity	TNFRSF4
Target	TNFRSF4
Isotype	IgG2
Source/Host	Human
Species Reactivity	Human
Clone	ivuxolimab
Purification	Purified from cell culture supernatant by affinity chromatography
Conjugate	unconjugated
Applications	FC
Reconstitution	Reconstitute with deionized water
Format	Powder
Size	50 µg, 100 µg
Buffer	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose is added as protectants before lyophilization.
Preservative	0.1% Procline 300

45-1 Ramsey Road, Shirley, NY 11967, USA
Email: info@creative-diagnostics.com
Tel: 1-631-624-4882 Fax: 1-631-938-8221

Storage	Store at -20°C (Avoid repeated freezing and thawing)

BACKGROUND

Introduction	Tumor necrosis factor receptor superfamily, member4, also known as ACT35 or CD134 is a cell surface glycoprotein that was discovered through the production of a monoclonal antibody raised against the HUT-102 cell line. It belongs to the tumor necrosis factor receptor superfamily. CD134 was mapped to 1p36 by fluorescence in situ hybridization. CD134 is the primary receptor for feline immunodeficiency virus. CD134 expression can promote viral binding and renders cells permissive for viral entry, productive infection, and syncytium formation. Stimulating the receptor can improve the response to a powerful virus vector and may be useful in vaccine development.
Keywords	TNFRSF4; OX40; CD134; OX40L receptor; ACT35; TXGP1L

GENE INFORMATION

Entrez Gene ID	7293

45-1 Ramsey Road, Shirley, NY 11967, USA
Email: info@creative-diagnostics.com
Tel: 1-631-624-4882 Fax: 1-631-938-8221